@article{ref1,
title="Suicidal overdose of dolutegravir: A case report"",
journal="Southern African journal of HIV medicine",
year="2018",
author="Daimari, R. and Kwape, L. and Oyekunle, A.A.",
volume="19",
number="1",
pages="-",
abstract="Dolutegravir (DTG) is the most recently introduced integrase inhibitor for the treatment of HIV infection and is preferred for its superior tolerability and efficacy in both new and pre- treated patients, and infrequent drug interactions. Since January 2017, Botswana has adopted a 'treat-air approach with a DTC-based antiretroviral (ARV) regimen as first-line treatment. We report a 29-year-old man with clinical stage 1 IIIV infection who had been started on DTG, tenofovir and emtricitabine eight months prior, and who was admitted following a suicidal overdose of 1500 mg of DTG. He reported only minor symptoms including vomiting, epigastric pain and dizziness; which promptly resolved following supportive treatment. On admission, full blood count, liver function tests and electrocardiography were unremarkable. However, there was a non-progressive increase in serum creatinine. After a month off ARVs, he was successfully restarted on antiretroviral therapy without any serious adverse effect 2018. The Authors. © 2018 AOSIS (pty) Ltd. All rights reserved.<p /><p>Language: en</p>",
language="en",
issn="1608-9693",
doi="10.4102/SAJHIVMED.V19I1.799",
url="http://dx.doi.org/10.4102/SAJHIVMED.V19I1.799"
}